Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Anemia and inflammation are prevalent in diabetic patients with chronic kidney disease (CKD). The role of endogenous erythropoietin (EPO) in the pathophysiology of anemia in chronic diseases and its relationship to clinical outcomes remain uncertain. In this cohort study, we aimed to identify factors associated with endogenous EPO levels and investigate their relation to all-cause mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between 2004 and 2005, 215 patients with type 2 diabetes were enrolled. Exclusion criteria included stage renal disease ESRD and any form of anemia therapy. The association of EPO levels with clinical and laboratory variables was investigated by linear regression modeling. Predictors of all-cause mortality were evaluated by Cox proportional hazards analyses. RESULTS: Patients (median age, 67 years; 52% men; median duration of diabetes, 10 years; median estimated GFR, 49 ml/min per 1.73 m²) were followed for up to 7.0 years. Forty-one patients died. Elevated EPO levels were independently associated with elevated C-reactive protein, low ferritin, and hypertension, in a multivariate model that also included age, cardiovascular disease, kidney function, albumin, cholesterol, and hemoglobin. Higher EPO levels were independently predictive for mortality, as were age, low levels of albumin, and cardiovascular disease. CONCLUSIONS: In diabetic patients with CKD, elevated endogenous EPO levels were predictive for mortality and were related mainly to markers of inflammation, independent of kidney function, and despite low hemoglobin levels. Understanding the phenomenon of EPO resistance and iron dysregulation caused by inflammation is crucial for effective and safe treatment of anemia in patients with CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“The acute phase protein hepcidin appears to have an important role, itself being regulated by iron and cytokines (29).”
BackgroundAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Self-citationRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Regulation of ferritin genes and protein
Torti, F. M., & Torti, S. V. (2002) · Blood · doi:10.1182/blood.v99.10.3505 · Cited by 1,173 · cited 1×
“Although we excluded patients with obvious absolute iron deficiency (ferritin, 30 g/L), we found evidence for diminished iron availability as expressed by an inverse relationship between EPO and ferritin (a marker of iron storage as well as an acute phase reactant) (30), even after adjustment for variables that reflec…”
BackgroundEzekowitz, J. A., McAlister, F. A., & Armstrong, P. W. (2003) · Circulation · doi:10.1161/01.cir.0000052622.51963.fc · Cited by 866
Molecular control of iron transport
Ganz, T. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070802 · Cited by 353 · cited 2×
“We could not separate iron deficiency from iron dysregulation under the influence of inflammation, because we did not have measurements of soluble transferrin receptor (11) or hepcidin (10).”
BackgroundFerrucci, L., Guralnik, J. M., Bandinelli, S., Semba, R. D., Lauretani, F., Corsi, A., Ruggiero, C., Ershler, W. B., & Longo, D. L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06502.x · Cited by 149
Cited by
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Update on Inflammation in Chronic Kidney Disease
Akchurin, O. M., & Kaskel, F. (2015) · Blood Purification · doi:10.1159/000368940 · Cited by 603
Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010263 · Cited by 519
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642296 · Cited by 369
Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease
Podkowińska, A., & Formanowicz, D. (2020) · Antioxidants · doi:10.3390/antiox9080752 · Cited by 356
Metadata
- Authors
- Wagner, M., Alam, A., Zimmermann, J., Rauh, K., Koljaja-Batzner, A., Raff, U., Wanner, C., & Schramm, L.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-07
- Volume
- 6
- Issue
- 7
- Pages
- 1573-1579
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2139810528
- Cited by
- 64
- References
- 8
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.00380111
- The paper
- Wagner, M., Alam, A., Zimmermann, J., Rauh, K., Koljaja-Batzner, A., Raff, U., Wanner, C., & Schramm, L. (2011). Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00380111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.